ES2097536T3 - Perlas dotadas de un nucleo con un antifungico y un polimero. - Google Patents

Perlas dotadas de un nucleo con un antifungico y un polimero.

Info

Publication number
ES2097536T3
ES2097536T3 ES93919206T ES93919206T ES2097536T3 ES 2097536 T3 ES2097536 T3 ES 2097536T3 ES 93919206 T ES93919206 T ES 93919206T ES 93919206 T ES93919206 T ES 93919206T ES 2097536 T3 ES2097536 T3 ES 2097536T3
Authority
ES
Spain
Prior art keywords
pearls
nucleus
antifungal
polymer
given
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93919206T
Other languages
English (en)
Inventor
Paul M V Gilis
Conde Valentin F V De
Roger P G Vandecruys
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8210890&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2097536(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of ES2097536T3 publication Critical patent/ES2097536T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Materials For Medical Uses (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A PERLAS, COMPRENDIENDO UN NUCLEO RETICULADO DE 25-30, UNA PELICULA DE REVESTIMIENTO DE UN POLIMERO HIDROFILICO Y UN AGENTE ANTIFUNGICO, Y UNA CAPA DE REVESTIMIENTO DE ESTANQUEIDAD; FORMAS DE DOSIFICACION FARMACEUTICA, COMPRENDIENDO LAS CITADAS PERLAS, Y UN METODO PARA PREPARAR LAS CITADAS PERLAS.
ES93919206T 1992-09-03 1993-08-27 Perlas dotadas de un nucleo con un antifungico y un polimero. Expired - Lifetime ES2097536T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP92202664 1992-09-03

Publications (1)

Publication Number Publication Date
ES2097536T3 true ES2097536T3 (es) 1997-04-01

Family

ID=8210890

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93919206T Expired - Lifetime ES2097536T3 (es) 1992-09-03 1993-08-27 Perlas dotadas de un nucleo con un antifungico y un polimero.

Country Status (33)

Country Link
US (1) US5633015A (es)
EP (1) EP0658103B1 (es)
JP (1) JP2865869B2 (es)
KR (1) KR0151893B1 (es)
CN (1) CN1034714C (es)
AP (1) AP444A (es)
AT (1) ATE145327T1 (es)
AU (1) AU665867B2 (es)
CA (1) CA2142848C (es)
CY (1) CY2105B1 (es)
CZ (1) CZ283403B6 (es)
DE (1) DE69306119T2 (es)
DK (1) DK0658103T3 (es)
ES (1) ES2097536T3 (es)
FI (1) FI112437B (es)
GR (1) GR3022198T3 (es)
HK (1) HK1006000A1 (es)
HR (1) HRP931158B1 (es)
HU (1) HU220614B1 (es)
IL (1) IL106871A (es)
MX (1) MX9305438A (es)
MY (1) MY109369A (es)
NO (1) NO307953B1 (es)
NZ (1) NZ255379A (es)
OA (1) OA10130A (es)
PH (1) PH30929A (es)
PL (2) PL174178B1 (es)
RU (1) RU2125445C1 (es)
SG (1) SG48801A1 (es)
SI (1) SI9300461B (es)
TW (1) TW376322B (es)
WO (1) WO1994005263A1 (es)
ZA (1) ZA936493B (es)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9325445D0 (en) 1993-12-13 1994-02-16 Cortecs Ltd Pharmaceutical formulations
EP0869847B1 (en) 1995-05-09 2003-03-05 Phoqus Limited Electrostatic coating
US7008668B2 (en) 1995-05-09 2006-03-07 Phoqus Pharmaceuticals Limited Powder coating composition for electrostatic coating of pharmaceutical substrates
US5750147A (en) * 1995-06-07 1998-05-12 Emisphere Technologies, Inc. Method of solubilizing and encapsulating itraconazole
DK0904060T3 (da) 1996-05-20 2004-04-13 Janssen Pharmaceutica Nv Antifungale præparater med forbedret biotilgængelighed
US5846971A (en) * 1996-06-28 1998-12-08 Schering Corporation Oral antifungal composition
HUP9903869A3 (en) * 1996-06-28 2000-07-28 Schering Corp Oral composition comprising a triazole antifungal compound
GB9623634D0 (en) 1996-11-13 1997-01-08 Bpsi Holdings Inc Method and apparatus for the coating of substrates for pharmaceutical use
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
PT969821E (pt) * 1997-03-26 2003-10-31 Janssen Pharmaceutica Nv Pastilhas tendo um nucleo revestido com um antifungico e um polimero
KR19990001564A (ko) * 1997-06-16 1999-01-15 유충식 용해도를 개선한 아졸계 항진균제 및 이를 함유하는 제제
JP3696087B2 (ja) * 1997-12-31 2005-09-14 チョンワエ ファーマ コーポレーション イトラコナゾール（ｉｔｒａｃｏｎａｚｏｌｅ）経口用製剤及びその製造方法
KR100514330B1 (ko) * 1997-12-31 2006-02-17 주식회사 중외제약 난용성 약물을 함유하는 코팅정
DE19808634A1 (de) * 1998-02-24 1999-08-26 Schering Ag Mantel für eine pharmazeutische Zusammensetzung
UA65607C2 (uk) 1998-03-04 2004-04-15 Орто-Макнейл Фармацевтикал, Інк. Фармацевтична композиція (варіанти) та спосіб її приготування
SI1104291T1 (sl) 1998-07-17 2006-02-28 Janssen Pharmaceutica Nv Pelete, ki imajo jedro oblozeno s fungicidom in polimerom
ES2157731B1 (es) * 1998-07-21 2002-05-01 Liconsa Liberacion Controlada Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion.
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
BR0009176A (pt) 1999-03-24 2001-12-18 Fmc Corp Partìcula granular, forma de dosagem, métodopara preparar uma partìcula granular, misturaseca, e, formulação granular
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20060034937A1 (en) * 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
KR100694667B1 (ko) * 1999-12-08 2007-03-14 동아제약주식회사 생체내이용률 향상과 개인간 및 개인내 흡수 편차를감소시킨 이트라코나졸 함유 항진균성 제제
AU2331801A (en) * 1999-12-23 2001-07-09 F.H. Faulding & Co. Limited Improved pharmaceutical compositions for poorly soluble drugs
CN101444511B (zh) * 2000-02-29 2013-01-02 布里斯托尔-迈尔斯斯奎布公司 低剂量艾替开韦制剂及其应用
US6551608B2 (en) * 2000-03-06 2003-04-22 Porex Technologies Corporation Porous plastic media with antiviral or antimicrobial properties and processes for making the same
US6977085B2 (en) * 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US6673373B2 (en) * 2001-02-01 2004-01-06 Carlsbad Technology Inc. Antifungal formulation and the methods for manufacturing and using the same
US6663897B2 (en) * 2001-02-06 2003-12-16 Dsm Ip Assets B.V. Oral itraconazole formulations and methods of making the same
CZ304273B6 (cs) 2001-02-14 2014-02-12 Tibotec Pharmaceuticals Ltd. 2-(Substitovaná-amino)benzothiazolsulfonamidová sloučenina, způsob její přípravy a farmaceutická kompozice s jejím obsahem
NZ528954A (en) 2001-04-09 2005-04-29 Tibotec Pharm Ltd Broadspectrum 2-(substituted-amino)-benzoxazole sulfonamide HIV protease inhibitors
PL209029B1 (pl) 2001-05-11 2011-07-29 Tibotec Pharm Ltd Pochodne 2-aminobenzoksazolo-sulfonamidów jako inhibitory proteazy HIV, oraz kompozycje zawierające te związki
AU4061702A (en) * 2001-05-15 2003-04-03 Mcneil-Ppc, Inc. Dip coating compositions containing starch or dextrin
US20030070584A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
KR100438485B1 (ko) * 2001-08-13 2004-07-09 한국디디에스제약 주식회사 아졸류 항진균제의 약제학적 조성물
US8071133B2 (en) 2001-08-20 2011-12-06 Stiefel Laboratories, Inc. Oral dosage forms of water insoluble drugs and methods of making the same
US8309118B2 (en) * 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
CA2363376A1 (en) * 2001-11-16 2003-05-16 Bernard Charles Sherman Solid pharmaceutical compositions for oral administration comprising itraconazole
BR0215260A (pt) 2001-12-21 2004-12-07 Tibotec Pharm Ltd Inibidores de hiv protease de sulfonamida contendo fenila substituìda heterocìclica de amplo espectro
US20030224006A1 (en) 2002-03-01 2003-12-04 Zaworotko Michael J. Multiple-component solid phases containing at least one active pharmaceutical ingredient
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
WO2003101392A2 (en) * 2002-05-31 2003-12-11 Transform Pharmaceuticals, Inc. Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7446107B2 (en) * 2002-02-15 2008-11-04 Transform Pharmaceuticals, Inc. Crystalline forms of conazoles and methods of making and using the same
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
MY142238A (en) 2002-03-12 2010-11-15 Tibotec Pharm Ltd Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors
IL165043A0 (en) 2002-05-17 2005-12-18 Tibotec Pharm Ltd broadspectrum substituted benzisoxazole sulfonamide hiv protease inhibitors
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
JP2006500377A (ja) * 2002-06-21 2006-01-05 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 改善された溶解性を有する医薬組成物
WO2004009120A1 (en) * 2002-07-22 2004-01-29 Nanohybrid Co., Ltd. Hybrid of itraconazole, cyclosporine or carvedilol with a layered silicate and a process for preparing the same
US7429619B2 (en) * 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
MXPA05001792A (es) 2002-08-14 2005-04-25 Tibotec Pharm Ltd Oxindolsulfonamida sustituida como inhibidores de proteasa de virus de inmunodeficiencia humana de amplio espectro.
WO2007014130A2 (en) * 2005-07-21 2007-02-01 Nomir Medical Technologies, Inc. Near infrared microbial elimination laser system (nimels)
US20040086567A1 (en) * 2002-10-30 2004-05-06 Pawan Seth Bioequivalent composition of itraconazole and a hydrophilic polymer
AU2002352938B8 (en) 2002-11-26 2009-10-08 The University Of Chicago Materials and methods for preventing and treating microbe-mediated epithelial disorders
US8183290B2 (en) * 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
ES2283725T5 (es) † 2003-01-14 2014-11-28 Acino Pharma Ag Composición bioequivalente de itraconazol dispersada en un polímero hidrófilo
SI1438960T2 (sl) * 2003-01-14 2013-04-30 Cimex Pharma Ag Sestavek itrakonazola, dispergiranega v hidrofilnem polimeru, z izboljšano biorazpoložljivostjo
FR2852607B1 (fr) * 2003-03-20 2006-07-14 Procede de fabrication de microspheres de sucre de petite taille, les microspheres susceptibles d'etre obtenues par ce procede et leurs applications
MXPA06002780A (es) 2003-09-11 2006-06-14 Tibotec Pharm Ltd Inhibidores de entrada del virus de vih.
US20050074494A1 (en) * 2003-10-06 2005-04-07 Xiu-Xiu Cheng Itraconazole immediate release formulation
US20050118265A1 (en) * 2003-11-28 2005-06-02 Anandi Krishnan Antifungal oral dosage forms and the methods for preparation
US9247765B2 (en) 2004-01-14 2016-02-02 Omniactive Health Technologies Limited Stable beadlets of lipophilic nutrients
WO2005084639A2 (en) * 2004-03-03 2005-09-15 Spherics, Inc. Polymeric drug delivery system for hydrophobic drugs
AR048650A1 (es) 2004-05-04 2006-05-10 Tibotec Pharm Ltd Derivados de (1,10b-dihidro-2-(aminocarbonil-fenil)-5h-pirazolo[1,5 c][1,3]benzoxazin-5-il)fenil metanona como inhibidores de la replicacion viral del vih
CN1997363B (zh) 2004-05-07 2012-03-28 塞阔伊亚药品公司 抗耐药性反转录病毒蛋白酶抑制剂
KR20070015608A (ko) 2004-05-17 2007-02-05 티보텍 파마슈티칼즈 리미티드 1-헤테로사이클일-1,5-디히드로-피리도[3,2-ｂ]인돌-2-온
ES2351702T3 (es) 2004-05-17 2011-02-09 Tibotec Pharmaceuticals 1-fenil-1,5-dihidro-pirido[3,2-b]indol-2-onas 6,7,8,9-sustituidas útiles como agentes farmacéuticos antiinfecciosos.
US7622582B2 (en) 2004-05-17 2009-11-24 Tibotec Bvba Derivatives of 1-phenyl-benzofuro[3,2]pyridin-2(1H)-one
US20060045865A1 (en) * 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
WO2006026504A2 (en) * 2004-08-27 2006-03-09 Spherics, Inc. Mucoadhesive oral formulations of high permeability, high solubility drugs
US20100297248A1 (en) * 2004-09-01 2010-11-25 Board Of Regents, The University Of Texas System Encapsulated particles for amorphous stability enhancement
US20060045822A1 (en) 2004-09-01 2006-03-02 Board Of Regents, The University Of Texas System Plasma polymerization for encapsulating particles
FR2883179B1 (fr) 2005-03-18 2009-04-17 Ethypharm Sa Comprime enrobe
TW200710091A (en) 2005-04-11 2007-03-16 Tibotec Pharm Ltd (1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors
US20070148240A1 (en) * 2005-12-23 2007-06-28 Fang-Yu Lee Oral formulation containing itraconazole and methods for manufacturing and using the same
US7994187B2 (en) 2006-04-03 2011-08-09 Tibotec Pharmaceuticals Ltd. HIV inhibiting 3,4-dihydro-imidazo[4,5-B]pyridin-5-ones
CN101091725A (zh) * 2006-06-23 2007-12-26 天津天士力制药股份有限公司 一种中药颗粒及其制备方法
WO2008110534A1 (en) * 2007-03-13 2008-09-18 Sandoz Ag Pharmaceutical compositions of poorly soluble drugs
CN101283984B (zh) * 2007-04-12 2010-05-26 永胜药品工业股份有限公司 高生物使用率的经杀真菌剂和聚合物涂覆的核心微粒状物
US7314641B1 (en) 2007-04-18 2008-01-01 Everest Pharm. Industrial Co., Ltd. High-bioavailability particle coated with fungicide and polymer
JP2008280254A (ja) * 2007-05-08 2008-11-20 Everest Pharm Industrial Co Ltd 生体に使用される比率が高い、殺菌剤と重合物を塗粧してる核心微粒状物
JP5745855B2 (ja) 2007-11-28 2015-07-08 セコイア、ファーマシューティカルズ、インコーポレイテッドＳｅｑｕｏｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． シトクロムｐ４５０ ２ｄ６を阻害するための組成物および方法
CA2716348C (en) 2008-02-21 2017-04-04 Sequoia Pharmaceuticals, Inc. Diamide inhibitors of cytochrome p450
US8088451B2 (en) 2008-03-13 2012-01-03 Board Of Regents, The University Of Texas System Covalently functionalized particles for synthesis of new composite materials
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
SG174658A1 (en) * 2010-04-01 2011-10-28 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
WO2011146078A1 (en) * 2010-05-21 2011-11-24 Board Of Regents, The University Of Texas System Encapsulated particles for enteric release
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
NZ613167A (en) * 2010-12-16 2015-09-25 Univ Texas Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compounds
RU2671575C2 (ru) 2011-05-10 2018-11-02 Теравида, Инк. Применение солифенацина и стимуляторов слюноотделения в лечении гиперактивного мочевого пузыря
EP2863911A4 (en) 2012-06-21 2016-07-13 Mayne Pharma Int Pty Ltd ITRACONAZOLE COMPOSITIONS AND METHOD OF DOSING AND METHOD OF USE THEREOF
CN103948911B (zh) * 2014-04-23 2016-04-20 深圳市健元医药科技有限公司 一种棘白菌素类抗真菌药物缓释微球制剂及其制备方法
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
CN108697688A (zh) 2016-01-20 2018-10-23 塞拉维达公司 用于治疗多汗症的方法和组合物
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ223799A (en) * 1987-03-25 1989-12-21 Janssen Pharmaceutica Nv Azolylmethyl-dioxolanylmethoxyphenyl-piperazinyl-phenyl-triazolones and antimicrobial compositions
US4916134A (en) * 1987-03-25 1990-04-10 Janssen Pharmacuetica N.V. 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
US4855326A (en) * 1987-04-20 1989-08-08 Fuisz Pharmaceutical Ltd. Rapidly dissoluble medicinal dosage unit and method of manufacture
JPH01165520A (ja) * 1987-12-23 1989-06-29 Shin Etsu Chem Co Ltd 持続性製剤およびその製造方法
US5049374A (en) * 1989-11-28 1991-09-17 Dansereau Richard J Oral (coated bead) dosage form for sodium iodide I-131
US5213811A (en) * 1991-09-13 1993-05-25 Sterling Drug Inc. Oral sustained-release drug compositions

Also Published As

Publication number Publication date
TW376322B (en) 1999-12-11
NO307953B1 (no) 2000-06-26
FI112437B (fi) 2003-12-15
IL106871A (en) 1998-02-22
HRP931158A2 (en) 1995-06-30
CY2105B1 (en) 2002-04-26
ATE145327T1 (de) 1996-12-15
SI9300461B (en) 2001-12-31
PL174178B1 (pl) 1998-06-30
AP444A (en) 1996-01-19
NZ255379A (en) 1996-06-25
JPH08501092A (ja) 1996-02-06
CA2142848C (en) 1999-11-16
SG48801A1 (en) 1998-05-18
HUT70419A (en) 1995-10-30
JP2865869B2 (ja) 1999-03-08
RU2125445C1 (ru) 1999-01-27
DK0658103T3 (da) 1996-12-09
IL106871A0 (en) 1993-12-28
HU9500642D0 (en) 1995-04-28
ZA936493B (en) 1995-03-02
MY109369A (en) 1997-01-31
CN1034714C (zh) 1997-04-30
DE69306119T2 (de) 1997-03-13
EP0658103B1 (en) 1996-11-20
AU4954693A (en) 1994-03-29
MX9305438A (es) 1994-03-31
CA2142848A1 (en) 1994-03-17
PL307791A1 (en) 1995-06-26
US5633015A (en) 1997-05-27
OA10130A (en) 1996-12-18
EP0658103A1 (en) 1995-06-21
HRP931158B1 (en) 1999-02-28
DE69306119D1 (de) 1997-01-02
WO1994005263A1 (en) 1994-03-17
FI950975A (fi) 1995-03-02
AP9300563A0 (en) 1993-10-31
PL172676B1 (pl) 1997-11-28
FI950975A0 (fi) 1995-03-02
CZ54295A3 (en) 1995-09-13
NO950829D0 (no) 1995-03-02
SI9300461A (en) 1994-03-31
PH30929A (en) 1997-12-23
AU665867B2 (en) 1996-01-18
HU220614B1 (hu) 2002-03-28
HK1006000A1 (en) 1999-02-05
GR3022198T3 (en) 1997-03-31
NO950829L (no) 1995-05-02
CN1088432A (zh) 1994-06-29
KR0151893B1 (ko) 1998-10-15
CZ283403B6 (cs) 1998-04-15

Similar Documents

Publication Publication Date Title
ES2097536T3 (es) Perlas dotadas de un nucleo con un antifungico y un polimero.
UY24888A1 (es) Tabletas de oxacarbazepina recubiertas de pelicula
IT1091613B (it) Erogatore osmotico di agente attivo particolarmente di medicamento e procedimento per la sua fabbricazione
ES2060074T3 (es) Una preparacion farmaceutica de liberacion controlada y un metodo para su obtencion.
YU12591A (sh) Postupak za izradu transdermalnog terapijskog sistema sa aktivnom materijom tulobuterolom
FR2511357B1 (fr) Cis-platine microcristallin, son procede de preparation et composition pharmaceutique le contenant
AR002275A1 (es) Forma de dosificacion farmaceutica oral, procedimiento para la manufactura de una forma de dosificacion fija, y uso de dicha forma de dosificacionfarmaceutica oral.
DE69133623D1 (de) Haltende neue pharmazeutische formulierungen sowie verfahren zu deren herstellung
AR019933A1 (es) Granulos que tienen un nucleo recubierto con un agente antifungico y un polimero, un procedimiento para su preparacion, una forma de dosificacionfarmaceutica
CA1008346A (en) Layer material for the rapid chromatographic identification of fluid substances, method for the preparation thereof, and use thereof
SE8701479L (sv) Metod foer inneslutning av biologiskt verksamma preparat samt anvaendning daerav
ES2052816T3 (es) Una composicion para revestir granulos de farmacos.
IT1003512B (it) Apparecchio per l uso nella deter minazione in vitro di una sostanza attiva in un fluido corporale
MX9307196A (es) Forma retardadora para sustancias activas farmaceuticas.
GB833586A (en) Coated plastic films
BR7405912D0 (pt) Processo para a fabricacao de derivados de canfora e composicoes absorventes de raios ultra-violeta a base destes
DK160816C (da) Benzoyl-urinstof-derivater, fremgangsmaade til fremstilling af disse, fremgangsmaade til bekaempelse af insektangreb samt insekticidt middel indeholdende disse
NO960098L (no) Preparat i form av matriks-innesluttede små perler
SE8504796D0 (sv) Farmaceutiskt medel for lokal terapi av psoriasis
IT1113407B (it) Procedimento e dispositivo per la fabbricazione di vetro "piatto" ricoperto da una pellicola di ossidi metallici
MX9102325A (es) Formas de dosis farmaceuticas de almacalante y procedimiento para su obtencion.
AU468390B2 (en) Manufacture of tetramisole
TR199800008T1 (xx) Ametokain ihtiva eden suyla aktive edilebilir yap��kan matrisi.
NL7603227A (nl) Werkwijze ter bereiding van een optisch actief (alpha)-fenylglycine en tussenprodukten daarvan.
ATE10633T1 (de) Phenyl-chinolizidine, entsprechende pharmazeutische praeparate, die herstellung der wirkstoffe sowie entsprechende ausgangsverbindungen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 658103

Country of ref document: ES